Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib

Oncology Research and Treatment

Volumn 40, Issue 4, 2017, Pages 174-183

  Enewold, Lindsey ^a   Sharon, Elad ^a   Harlan, Linda C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Ipilimumab; Metastatic melanoma; Patterns of care; Survival; Treatment; Vemurafenib

Indexed keywords

ALPHA INTERFERON; AXITINIB; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DABRAFENIB; DACARBAZINE; DENOSUMAB; FARLETUZUMAB; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; NILOTINIB; PACLITAXEL; PAZOPANIB; PEGINTERFERON ALPHA2B; PEMBROLIZUMAB; PIDILIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; TEMOZOLOMIDE; VEMURAFENIB; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; OXIME; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DRUG MEGADOSE; FAMILY HISTORY; FEMALE; HAZARD RATIO; HEALTH INSURANCE; HISPANIC; HISTOPATHOLOGY; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MONOTHERAPY; POPULATION RESEARCH; SURVIVAL TIME; TREATMENT DURATION; TREATMENT INDICATION; ULCER; UNITED STATES; AGE DISTRIBUTION; EPIDEMIOLOGY; MELANOMA; MORTALITY; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; SEX RATIO; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; OXIMES; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; SKIN NEOPLASMS; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 85017133607     PISSN: 22965270     EISSN: 22965262     Source Type: Journal    
DOI: 10.1159/000456014     Document Type: Article

References (23)

1. American Cancer Society: Cancer Facts & Figures Atlanta, American Cancer Society, 2016.
2. Howlader N, Noone AM, Krapcho M, et al. (eds): SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
3. Agarwala SS: Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009; 9: 587-595.
4. Clemente CG, Mihm MC, Bufalino R, et al.: Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310.
5. Antony GK, Dudek AZ: Interleukin 2 in cancer therapy. Curr Med Chem 2010; 17: 3297-3302.
6. Kirkwood JM, Tarhini AA, Panelli MC, et al.: Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26: 3445-3455.
7. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
8. Robert C, Thomas L, Bondarenko I, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
9. McArthur GA, Chapman PB, Robert C, et al.: Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15: 323-332.
10. Omholt K, Platz A, Kanter L, et al.: NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483-6488.
11. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
12. National Cancer Institute. SEER Registry Groupings for Analyses. http://seer.cancer.gov/registries/terms. html Accessed: 03/2016.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-383.
14. Kleinbaum D: Survival analyses: A self-learning text. New York, Springer, 1996.
15. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence-SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) -Linked To County Attributes-Total U.S., 1969-2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.
16. Enewold L, Thomas A: Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One 2016; 11:e0156728.
17. Fellner C: Ipilimumab (Yervoy) prolongs survival in advanced melanoma: Serious side effects and a hefty price tag may limit its use. P T 2012; 37: 503-530.
18. Parikh AA, Robinson J, Zaydfudim VM, et al.: The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. J Surg Oncol 2014; 110: 227-232.
19. Warren JL, Butler EN, Stevens J, et al.: Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance. J Clin Oncol 2015; 33: 312-318.
20. Warren JL, Harlan LC, Stevens J, et al.: Multiple myeloma treatment transformed: A population-based study of changes in initial management approaches in the United States. J Clin Oncol 2013; 31: 1984-1989.
21. Pennisi M, Russo G, Di Salvatore V, et al.: Computational modeling in melanoma for novel drug discovery. Expert Opin Drug Discov 2016; 11: 609-621.
22. Russo A, Ficili B, Candido S, et al.: Emerging targeted therapies for melanoma treatment (review). Int J Oncol 2014; 45: 516-524.
23. Ribas A, Kim KB, Schuchter LM, et al.: BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAFV600E mutation-positive melanoma. J Clin Oncol 2011; 29(Suppl): 8509.